Glaukos Corporation shares rise 1.32% intraday after investor presentation in August 2024.

Glaukos Corporation rose 1.32% in intraday trading, with the company presenting its core growth strategy at an investor presentation in August 2024. The presentation highlighted Glaukos' commitment to leading-edge innovation, challenging conventional paradigms to advance the standards of care and improve outcomes. The company's focus on dropless therapies and commercial excellence in building durable new markets to better serve physicians and patients worldwide aligns with the positive stock movement.